DK0383472T3 - Insulinanaloger - Google Patents

Insulinanaloger

Info

Publication number: DK0383472T3
Authority: DK; Denmark
Prior art keywords: absent; lys; threonine; arg; aspartic acid
Prior art date: 1989-02-09

Application number

DK90301224.3T

Other languages

English (en)

Inventor

Ronald Eugene Chance

Richard Dennis Dimarchi

Bruce Hill Frank

James Edwin Shields

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1990-02-06

Publication date

1996-05-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0383472(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-02-06 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1996-05-06 Application granted granted Critical

1996-05-06 Publication of DK0383472T3 publication Critical patent/DK0383472T3/da

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 3
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 5
239000004473 Threonine Substances 0.000 abstract 5
235000003704 aspartic acid Nutrition 0.000 abstract 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 5
235000009582 asparagine Nutrition 0.000 abstract 4
229960001230 asparagine Drugs 0.000 abstract 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
229930182821 L-proline Natural products 0.000 abstract 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
235000004279 alanine Nutrition 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
229960002429 proline Drugs 0.000 abstract 2
239000004474 valine Substances 0.000 abstract 2
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 abstract 1
JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
229930028154 D-arginine Natural products 0.000 abstract 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 abstract 1
229930182820 D-proline Natural products 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 abstract 1
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
229940024606 amino acid Drugs 0.000 abstract 1
108010068380 arginylarginine Chemical group 0.000 abstract 1
108010062796 arginyllysine Chemical group 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
235000004554 glutamine Nutrition 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
108010054155 lysyllysine Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
PMMYEEVYMWASQN-IUYQGCFVSA-N trans-4-hydroxy-D-proline Chemical compound O[C@@H]1CN[C@@H](C(O)=O)C1 PMMYEEVYMWASQN-IUYQGCFVSA-N 0.000 abstract 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/622—Insulins at least 1 amino acid in D-form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Compounds Of Unknown Constitution (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK90301224.3T 1989-02-09 1990-02-06 Insulinanaloger DK0383472T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30835289A	1989-02-09	1989-02-09
US38820189A	1989-08-04	1989-08-04

Publications (1)

Publication Number	Publication Date
DK0383472T3 true DK0383472T3 (da)	1996-05-06

Family

ID=26976211

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK95200804T DK0678522T3 (da)	1989-02-09	1990-02-06	Insulinanaloger
DK90301224.3T DK0383472T3 (da)	1989-02-09	1990-02-06	Insulinanaloger

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK95200804T DK0678522T3 (da)	1989-02-09	1990-02-06	Insulinanaloger

Country Status (24)

Country	Link
EP (2)	EP0383472B1 (da)
JP (1)	JPH0822878B2 (da)
KR (1)	KR0169727B1 (da)
CN (2)	CN1034080C (da)
AT (1)	ATE133961T1 (da)
AU (1)	AU630912B2 (da)
BG (1)	BG60769B2 (da)
CA (1)	CA2009579C (da)
CY (1)	CY1911A (da)
DE (3)	DE69033889T2 (da)
DK (2)	DK0678522T3 (da)
ES (2)	ES2170122T3 (da)
FI (1)	FI95915C (da)
GR (1)	GR3019501T3 (da)
HK (1)	HK60296A (da)
HU (2)	HU212679B (da)
IE (1)	IE73251B1 (da)
IL (1)	IL93282A (da)
LU (2)	LU88831I2 (da)
NL (1)	NL960026I2 (da)
NO (2)	NO179587C (da)
NZ (1)	NZ232375A (da)
PT (1)	PT93057B (da)
RU (1)	RU2109749C1 (da)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5716927A (en) *	1988-12-23	1998-02-10	Novo Nordisk A/S	Insulin analogs having a modified B-chain
KR910700262A (ko) *	1988-12-23	1991-03-14	안네 제케르	사람 인슐린 유사체
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence
DK10191D0 (da) *	1991-01-22	1991-01-22	Novo Nordisk As	Hidtil ukendte peptider
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
IL102240A0 (en) *	1991-06-21	1993-01-14	Lilly Co Eli	Insulin analogs
GB9316895D0 (en)	1993-08-13	1993-09-29	Guy S And St Thomas Hospitals	Hepatoselective insulin analogues
US6131567A (en) *	1993-01-29	2000-10-17	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
EP1607086A1 (en) *	1993-01-29	2005-12-21	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) *	1993-06-21	1993-06-21	Novo Nordisk As	Nyt produkt
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5504188A (en)	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5559094A (en) *	1994-08-02	1996-09-24	Eli Lilly And Company	AspB1 insulin analogs
US5547929A (en) *	1994-09-12	1996-08-20	Eli Lilly And Company	Insulin analog formulations
US5597893A (en) *	1994-10-31	1997-01-28	Eli Lilly And Company	Preparation of stable insulin analog crystals
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
EP0741188A3 (en) *	1995-05-05	1999-07-14	Eli Lilly And Company	Single chain insulin with high bioactivity
US5700904A (en) *	1995-06-07	1997-12-23	Eli Lilly And Company	Preparation of an acylated protein powder
US5631347A (en) *	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
ATE208208T1 (de) *	1996-06-20	2001-11-15	Novo Nordisk As	Halogenid-enthaltende insulinzubereitungen
DK0821006T3 (da) *	1996-07-26	2004-08-16	Aventis Pharma Gmbh	Insulinderivater med öget zinkbinding
SE520392C2 (sv)	1996-09-27	2003-07-01	Creative Peptides Sweden Ab C	Specifika peptider för behandling av diabetes mellitus
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EA200000453A1 (ru)	1997-10-24	2000-10-30	Эли Лилли Энд Компани	Композиции нерастворимого инсулина
US6531448B1 (en)	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
US20010007853A1 (en) *	1998-01-08	2001-07-12	Dimarchi Richard Dennis	Method for administering monomeric insulin analogs
DE19805822B4 (de) *	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1125081C (zh) *	1999-09-08	2003-10-22	中国科学院上海生物化学研究所	重组天然和新型人胰岛素及其制备方法
US7202059B2 (en)	2001-02-20	2007-04-10	Sanofi-Aventis Deutschland Gmbh	Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en)	2001-02-20	2009-12-29	Sanofi-Aventis Deutschland Gmbh	Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1506003A1 (en) *	2002-05-07	2005-02-16	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en)	2002-10-29	2007-03-20	Sanofi-Aventis Deutschland Gmbh	Crystals of insulin analogs and processes for their preparation
RU2235776C1 (ru) *	2003-03-17	2004-09-10	Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова РАН	Рекомбинантная плазмидная днк plp-3,1, кодирующая полипептид проинсулина lyspro человека, и штамм бактерий escherichia coli plp-3-1/tg-1-продуцент рекомбинантного проинсулина lyspro
MXPA06001283A (es)	2003-08-05	2006-04-11	Novo Nordisk As	Derivados de insulina novedosos.
SI2107069T1 (sl)	2003-08-05	2013-04-30	Novo Nordisk A/S	Novi inzulinski derivati
EP1684793B1 (en) *	2003-11-13	2011-09-21	Novo Nordisk A/S	Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
TR201906789T4 (tr)	2003-11-20	2019-05-21	Novo Nordisk As	Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
CN1902226A (zh)	2003-12-03	2007-01-24	诺和诺德公司	单链胰岛素
BRPI0513508B1 (pt)	2004-07-19	2021-06-01	Biocon Limited	Conjugados de insulina-oligômero, formulações e usos desses
WO2006082204A1 (en)	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
EP1846447B1 (en)	2005-02-02	2013-08-21	Novo Nordisk A/S	Insulin derivatives
JPWO2006093222A1 (ja) *	2005-03-02	2008-08-07	味の素株式会社	インスリンの多量体形成阻害剤
CN102660614A (zh)	2005-08-16	2012-09-12	诺沃-诺迪斯克有限公司	制备成熟胰岛素多肽的方法
CA2621344C (en)	2005-09-14	2014-12-16	Sanofi-Aventis Deutschland Gmbh	Cleavage of precursors of insulins by a variant of trypsin
JP4808785B2 (ja)	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	インスリン組成物および組成物の製造方法
EP1991576B1 (en)	2006-02-27	2010-09-29	Novo Nordisk A/S	Insulin derivatives
JP5312054B2 (ja)	2006-03-15	2013-10-09	ノボ・ノルデイスク・エー／エス	アミリンとインスリンの混合物
MX2008014061A (es)	2006-05-09	2008-11-14	Novo Nordisk As	Derivado de insulina.
EP2024390B1 (en)	2006-05-09	2015-08-19	Novo Nordisk A/S	Insulin derivative
DK2074141T3 (da)	2006-09-22	2016-11-28	Novo Nordisk As	Proteaseresistente insulinanaloger.
US9387176B2 (en)	2007-04-30	2016-07-12	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US20110144010A1 (en)	2007-06-01	2011-06-16	Novo Nordisk A/S	Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
AU2008257505B2 (en)	2007-06-01	2013-05-16	Novo Nordisk A/S	Stable non-aqueous pharmaceutical compositions
US9034818B2 (en)	2007-06-13	2015-05-19	Novo Nordisk A/S	Pharmaceutical formulations comprising an insulin derivative
CN102007143B (zh)	2008-01-09	2015-08-26	塞诺菲-安万特德国有限公司	具有超延迟时效特征的新型胰岛素衍生物
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
CN102256618A (zh)	2008-10-17	2011-11-23	赛诺菲-安万特德国有限公司	胰岛素和glp-1激动剂的组合
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
AU2009309623B9 (en)	2008-10-30	2014-10-02	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2011003820A1 (de)	2009-07-06	2011-01-13	Sanofi-Aventis Deutschland Gmbh	Hitze- und schüttelstabile insulinzubereitungen
US20120232002A1 (en)	2009-07-06	2012-09-13	Sanofi-Aventis Deutschland Gmbh	Slow-acting insulin preparations
PL2451437T3 (pl)	2009-07-06	2017-05-31	Sanofi-Aventis Deutschland Gmbh	Wodne preparaty insuliny zawierające metioninę
PL2459171T3 (pl)	2009-07-31	2017-11-30	Sanofi-Aventis Deutschland Gmbh	Kompozycja insuliny o długim działaniu
AU2010277559B2 (en)	2009-07-31	2016-08-11	Sanofi-Aventis Deutschland Gmbh	Prodrugs comprising an insulin linker conjugate
TR201809460T4 (tr)	2009-11-13	2018-07-23	Sanofi Aventis Deutschland	Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en)	2009-11-13	2013-09-27	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
US20130143803A1 (en)	2010-05-10	2013-06-06	Novo Nordisk A/S	Process for the Preparation of Insulin-Zinc Complexes
WO2012028172A1 (en)	2010-08-30	2012-03-08	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (en)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Prodrugs comprising an exendin linker conjugate
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
CN103167878A (zh)	2010-10-27	2013-06-19	诺沃—诺迪斯克有限公司	采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
CN102199206B (zh) *	2011-03-17	2013-03-20	甘李药业股份有限公司	快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2872083A1 (en)	2012-05-01	2013-11-07	Novo Nordisk A/S	Pharmaceutical composition
US20130315891A1 (en)	2012-05-25	2013-11-28	Matthew Charles	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en)	2012-06-04	2017-02-22	Diamedica Inc.	Human tissue kallikrein 1 glycosylation isoforms
WO2014093696A2 (en)	2012-12-12	2014-06-19	Massachusetts Institute Of Technology	Insulin derivatives for diabetes treatment
US9707275B2 (en)	2012-12-19	2017-07-18	Wockhardt Limited	Stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (ja)	2012-12-26	2016-02-25	ウォックハートリミテッド	医薬組成物
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014161835A1 (en) *	2013-04-03	2014-10-09	Sanofi	Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
US20160271226A1 (en)	2013-09-30	2016-09-22	Wockhardt Limited	Pharmaceutical composition
CN105960249B (zh)	2014-01-09	2021-03-16	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
US9895423B2 (en)	2014-01-09	2018-02-20	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
JP6723921B2 (ja)	2014-01-09	2020-07-15	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
US10640546B2 (en) *	2014-06-10	2020-05-05	California Institute Of Technology	Non-canonical insulins and their uses
WO2016001862A1 (en)	2014-07-04	2016-01-07	Wockhardt Limited	Extended release formulations of insulins
PE20171622A1 (es)	2014-12-12	2017-11-02	Sanofi Aventis Deutschland	Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
RU2764197C1 (ru) *	2016-09-23	2022-01-14	Ханми Фарм. Ко., Лтд.	Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
DK3518892T5 (da)	2016-09-29	2024-09-02	Arecor Ltd	Farmaceutisk formulering, der indeholder en insulinforbindelse
CN110446501A (zh)	2017-03-09	2019-11-12	代阿麦迪卡股份有限公司	组织激肽释放酶1的剂型
GB201707188D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707189D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707187D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
CA3094304A1 (en)	2018-04-04	2019-10-10	Arecor Limited	Medical infusion pump system for the delivery of an insulin compound
CN112040928A (zh)	2018-04-04	2020-12-04	艾瑞克有限公司	用于递送胰岛素化合物的医用输注泵系统
IL277721B2 (en)	2018-04-04	2024-03-01	Arecor Ltd	Medical infusion pump system for the delivery of an insulin compound
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR20200082618A (ko)	2018-12-31	2020-07-08	주식회사 폴루스	인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
AU2020417892A1 (en)	2019-12-30	2022-08-25	Gan & Lee Pharmaceuticals Co., Ltd.	Insulin derivative
CN119529057A (zh)	2019-12-30	2025-02-28	甘李药业股份有限公司	长效glp-1化合物
GB202004814D0 (en)	2020-04-01	2020-05-13	Arecor Ltd	Novel formulations
CN118574842A (zh)	2022-01-28	2024-08-30	甘李药业股份有限公司	酰化胰岛素

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3101382A1 (de) *	1981-01-17	1982-09-02	Hoechst Ag, 6000 Frankfurt	"verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK129385A (da) *	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence

1990
- 1990-02-05 PT PT93057A patent/PT93057B/pt active IP Right Grant
- 1990-02-05 NZ NZ232375A patent/NZ232375A/en unknown
- 1990-02-05 IL IL9328290A patent/IL93282A/en not_active IP Right Cessation
- 1990-02-06 DE DE69033889T patent/DE69033889T2/de not_active Expired - Lifetime
- 1990-02-06 LU LU88831C patent/LU88831I2/fr unknown
- 1990-02-06 DE DE1990625210 patent/DE19675034I2/de active Active
- 1990-02-06 ES ES95200804T patent/ES2170122T3/es not_active Expired - Lifetime
- 1990-02-06 DE DE69025210T patent/DE69025210T2/de not_active Expired - Lifetime
- 1990-02-06 ES ES90301224T patent/ES2083424T3/es not_active Expired - Lifetime
- 1990-02-06 DK DK95200804T patent/DK0678522T3/da active
- 1990-02-06 EP EP90301224A patent/EP0383472B1/en not_active Expired - Lifetime
- 1990-02-06 DK DK90301224.3T patent/DK0383472T3/da active
- 1990-02-06 CY CY191190A patent/CY1911A/xx unknown
- 1990-02-06 AT AT90301224T patent/ATE133961T1/de active
- 1990-02-06 LU LU88830C patent/LU88830I2/fr unknown
- 1990-02-06 EP EP95200804A patent/EP0678522B1/en not_active Expired - Lifetime
- 1990-02-07 FI FI900600A patent/FI95915C/fi active IP Right Grant
- 1990-02-07 IE IE44090A patent/IE73251B1/en not_active IP Right Cessation
- 1990-02-07 AU AU49226/90A patent/AU630912B2/en not_active Expired
- 1990-02-08 NO NO900615A patent/NO179587C/no not_active IP Right Cessation
- 1990-02-08 KR KR1019900001498A patent/KR0169727B1/ko not_active Expired - Lifetime
- 1990-02-08 CA CA002009579A patent/CA2009579C/en not_active Expired - Lifetime
- 1990-02-08 HU HU90726A patent/HU212679B/hu unknown
- 1990-02-08 CN CN90101415A patent/CN1034080C/zh not_active Expired - Lifetime
- 1990-02-08 JP JP2031347A patent/JPH0822878B2/ja not_active Expired - Lifetime
1991
- 1991-11-21 RU SU5010208A patent/RU2109749C1/ru active
1994
- 1994-02-25 BG BG098572A patent/BG60769B2/bg unknown
1995
- 1995-06-07 HU HU95P/P00171P patent/HU211276A9/hu unknown
1996
- 1996-04-02 GR GR960400889T patent/GR3019501T3/el unknown
- 1996-04-03 HK HK60296A patent/HK60296A/en not_active IP Right Cessation
- 1996-05-23 CN CN96106635A patent/CN1103602C/zh not_active Ceased
- 1996-10-17 NL NL960026C patent/NL960026I2/nl unknown
- 1996-12-09 NO NO1996013C patent/NO1996013I1/no unknown

Also Published As

Publication number	Publication date
DK0678522T3 (da)	2002-03-11
IL93282A (en)	1995-08-31
EP0383472B1 (en)	1996-02-07
ES2083424T3 (es)	1996-04-16
NO179587B (no)	1996-07-29
EP0678522B1 (en)	2002-01-02
KR900012627A (ko)	1990-09-01
NO1996013I1 (no)	1996-12-09
EP0383472A3 (en)	1991-09-18
DE69025210T2 (de)	1996-06-13
DE19675034I2 (de)	2006-11-16
FI95915B (fi)	1995-12-29
PT93057A (pt)	1990-08-31
EP0678522A1 (en)	1995-10-25
AU4922690A (en)	1990-08-16
IL93282A0 (en)	1990-11-29
NL960026I2 (nl)	1997-05-01
IE900440L (en)	1990-08-09
JPH02264798A (ja)	1990-10-29
BG60769B2 (bg)	1996-02-29
CA2009579C (en)	2000-04-11
HU900726D0 (en)	1990-04-28
KR0169727B1 (ko)	1999-01-15
HK60296A (en)	1996-04-12
ATE133961T1 (de)	1996-02-15
DE69033889T2 (de)	2002-08-22
DE69033889D1 (de)	2002-02-07
NO179587C (no)	1996-11-06
JPH0822878B2 (ja)	1996-03-06
NL960026I1 (nl)	1997-01-06
DE69025210D1 (de)	1996-03-21
LU88831I2 (fr)	1997-01-10
AU630912B2 (en)	1992-11-12
EP0383472A2 (en)	1990-08-22
PT93057B (pt)	1995-12-29
CN1103602C (zh)	2003-03-26
CN1044820A (zh)	1990-08-22
LU88830I2 (fr)	1997-01-06
IE73251B1 (en)	1997-05-21
CN1148984A (zh)	1997-05-07
CY1911A (en)	1990-02-06
FI95915C (fi)	1996-04-10
NO900615L (no)	1990-08-10
HU212679B (en)	1996-09-30
HU211276A9 (en)	1995-11-28
NO900615D0 (no)	1990-02-08
CA2009579A1 (en)	1990-08-09
ES2170122T3 (es)	2002-08-01
NZ232375A (en)	1992-04-28
CN1034080C (zh)	1997-02-19
HUT57795A (en)	1991-12-30
FI900600A0 (fi)	1990-02-07
RU2109749C1 (ru)	1998-04-27
GR3019501T3 (en)	1996-07-31

Publication	Publication Date	Title
DK0383472T3 (da)	1996-05-06	Insulinanaloger
EP0512042A4 (en)	1993-02-17	Glp-1 analogs useful for diabetes treatment
PE47096A1 (es)	1996-11-12	Analogo, composicion y uso del peptido insulinotropico similar al glucagon
NZ517012A (en)	2003-02-28	Peptides that lower blood glucose levels
HU906177D0 (en)	1991-08-28	Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
ATE99699T1 (de)	1994-01-15	Peptide.
ES2060100T3 (es)	1994-11-16	Microproteinas, procedimiento de preparacion, y aplicacion como medicamentos de estas proteinas.
FI925972A0 (fi)	1992-12-31	Ny polypeptid med affinitet till lipopolysackarider och dess anvaendning
DK424989A (da)	1990-03-01	Rekombinant, naturlig, draebercelleaktiverende faktor
KR910002899A (ko)	1991-02-26	혈조절 펩타이드
DE69302921D1 (de)	1996-07-11	Neue Peptidderivate, Verfahren zu deren Herstellung und deren Anwendung als Heilmittel
ES2135389T3 (es)	1999-11-01	Antagonistas de endotelina.
ATE207496T1 (de)	2001-11-15	Neue peptide und nootroper wirkstoff
RU93004930A (ru)	1996-01-27	Днк, соматотропин, плазмиды, рекомбинантные организмы, композиция, способ получения соматотропина, способы стимулирования роста